APA (7th ed.) Citation

M, G., M, J., RS, H., GI, S., S, P., FH, W., . . . J, T. (2025). MAT2A inhibitor AG-270/S095033 in patients with advanced malignancies: A phase I trial. Nature communications, 16(1), 423. https://doi.org/10.1038/s41467-024-55316-5

Chicago Style (17th ed.) Citation

M, Gounder, et al. "MAT2A Inhibitor AG-270/S095033 in Patients with Advanced Malignancies: A Phase I Trial." Nature Communications 16, no. 1 (2025): 423. https://doi.org/10.1038/s41467-024-55316-5.

MLA (9th ed.) Citation

M, Gounder, et al. "MAT2A Inhibitor AG-270/S095033 in Patients with Advanced Malignancies: A Phase I Trial." Nature Communications, vol. 16, no. 1, 2025, p. 423, https://doi.org/10.1038/s41467-024-55316-5.